| (Values in U.S. Thousands) | Nov, 2022 | Nov, 2021 | Nov, 2020 | Nov, 2022 | Nov, 2021 |
| Sales | 0 | 0 | 416 | 0 | 0 |
| Sales Growth | unch | -100.00% | unch | unch | unch |
| Net Income | -2,034 | -7,208 | -2,677 | 0 | 0 |
| Net Income Growth | +71.77% | -169.22% | unch | unch | unch |
Neonmind Biosciences Inc (NEON.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
NeonMind Biosciences Inc is engaged in drug development research into potential therapeutic uses of psychedelic compounds. The company operates two divisions: a pharmaceutical division engaged in drug development of psychedelic compounds with two psilocybin-based drug candidates targeting obesity; a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.